Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about ImmunoGen, Inc.
ImmunoGen, Inc. News
ImmunoGen, Inc. Quantitative Score
About ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
ImmunoGen, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
ImmunoGen, Inc. Financials
Table Compare
Compare IMGN metrics with: | |||
|---|---|---|---|
Earnings & Growth | IMGN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | IMGN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | IMGN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | IMGN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
ImmunoGen, Inc. Income
ImmunoGen, Inc. Balance Sheet
ImmunoGen, Inc. Cash Flow
ImmunoGen, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Buy |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
ImmunoGen, Inc. Executives
| Name | Role |
|---|---|
| Mr. Mark Joseph Enyedy | President, Chief Executive Officer & Director |
| Dr. Theresa G. Wingrove | Senior Vice President of Regulatory Affairs & Quality |
| Dr. Michael J. Vasconcelles M.D., Ph.D. | Chief Medical Officer |
| Mr. Daniel S. Char J.D. | Senior Vice President, Chief Legal Officer & Secretary |
| Ms. Audrey Bergan | Senior Vice President & Chief HR Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Mark Joseph Enyedy | President, Chief Executive Officer & Director | Male | 1964 | 1.28M |
| Dr. Theresa G. Wingrove | Senior Vice President of Regulatory Affairs & Quality | 1958 | 548.21K | |
| Dr. Michael J. Vasconcelles M.D., Ph.D. | Chief Medical Officer | 1963 | 304.62K | |
| Mr. Daniel S. Char J.D. | Senior Vice President, Chief Legal Officer & Secretary | Male | 1962 | -- |
| Ms. Audrey Bergan | Senior Vice President & Chief HR Officer | Female | -- |
ImmunoGen, Inc. Insider Trades
| Date | 12 Feb |
| Name | MITCHELL DEAN J |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 103000 |
| Date | 12 Feb |
| Name | MITCHELL DEAN J |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 13090 |
| Date | 12 Feb |
| Name | MITCHELL DEAN J |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 142667 |
| Date | 12 Feb |
| Name | MITCHELL DEAN J |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 10000 |
| Date | 12 Feb |
| Name | MITCHELL DEAN J |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 10000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 12 Feb | MITCHELL DEAN J | Director | Disposed | D-Return | 103000 |
| 12 Feb | MITCHELL DEAN J | Director | Disposed | D-Return | 13090 |
| 12 Feb | MITCHELL DEAN J | Director | Disposed | D-Return | 142667 |
| 12 Feb | MITCHELL DEAN J | Director | Disposed | D-Return | 10000 |
| 12 Feb | MITCHELL DEAN J | Director | Disposed | D-Return | 10000 |